Call for papers: Role of Synthetic Biology and Gene Engineering in CAR Immunotherapy
BMC Biotechnology is currently accepting submissions to a thematic series entitled ' Role of Synthetic Biology and Gene Engineering in CAR Immunotherapy'.
Chimeric antigen receptor (CAR) T cells therapies, as a cancer immunotherapy, have provided significant benefit in treating cancer.
To present the recent advances in the theory and application of CAR immunotherapy, we invite you and/or members of your research team to provide a manuscript for this thematic series.
Your submission could take the form of original research, review, or commentary.
Deadline for submission to the collection: 30th June 2018.
The molecular engineering of chimeric T cell receptors opens a window onto interactions between a cytotoxic T cell and a cancer cell with exciting implications for immunotherapy.
Aims and scope
- Ying Lou, BioMed Central
- Ayelet Fishman,Technion
- Joaquim M Cabral, Instituto Superior Tecnico
- Dennis Claessen, Leiden University
- Peter J Punt, TNO Microbiology & Systems Biology/Leiden University
- Marko Radic, University of Tennessee
- John J Rossi, Beckman Research Institute City of Hope
- Igor Stagljar, University of Toronto
- Neal C Stewart, University of Tennessee
Data Support Services pilot
Authors submitting to this journal can opt to use a new service that will make it easier to share research data.
BMC Series blog
10 November 2017
06 November 2017
31 October 2017